Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Yang, Hui ^a,b   Zhang, Chao ^a   Zhou, Quanyu ^c   Wang, Yike ^c   Chen, Lujia ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c First People's Hospital of Lianyungang   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM;

ABDOMINAL INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONFUSION; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TOLERABILITY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; TACHYCARDIA; TONIC CLONIC SEIZURE; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; MICROBIOLOGY; ODDS RATIO; RENAL INSUFFICIENCY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; ODDS RATIO; PENICILLANIC ACID; PIPERACILLIN; RENAL INSUFFICIENCY; TACHYCARDIA;

EID: 84920830693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116769     Document Type: Review

References (45)

1. Mah GT, Mabasa VH, Chow I, Ensom MH (2012) Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. Ann Pharmacother 46: 265-75. doi: 10.1345/aph.1Q378
2. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, et al. (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 5: 133-64. doi: 10.1086/ 649554
3. Javad A, Vahid P, Kazem G, Alireza S, Gholamali G, et al. (2006) Piperacillin/tazobactam in treatment of brain abscess. Scand J Infect Dis 38: 224-6. doi: 10.1080/00365540500348978 PMID: 16500789
4. Lodise TP, Lomaestro BM, Drusano GL (2006) Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics. Pharmacotherapy 26: 1320-32. doi: 10.1592/phco. 26.9.1320 PMID: 16945055
5. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J (2007) Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30: 11-8. doi: 10.1016/j. ijantimicag.2007.02.002 PMID: 17442541
6. Fehér C, Rovira M, Soriano A, Esteve J, Martínez JA, et al. (2014) Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother: 69:2556-62. doi: 10.1093/jac/dku150 PMID: 24855125
7. Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, et al. (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523-7. doi: 10.1093/jac/43.4.523 PMID: 10350382
8. Bauer KA, West JE, O'Brien JM, Goff DA (2013) Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 7: 2907-12. doi: 10. 1128/AAC.02365-12
9. Papich MG (2014) Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Vet Microbiol 16: 480-6. doi: 10.1016/j. vetmic.2013.12.021
10. Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, et al. (2013) Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 57: 5811-9. doi: 10.1128/AAC.00867-13 PMID: 24002098
11. De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, et al. (2014) Therapeutic drug monitoringbased dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med, 40:380-7. doi: 10.1007/s00134-013-3187-2 PMID: 24356862
12. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, et al. (2005) Pharmacokinetics of piper-acillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25: 62-7. doi: 10.1016/j.ijantimicag.2004.08.012 PMID: 15620828
13. Drusano GL (2003) Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36:S42-50. doi: 10.1086/344653 PMID: 12516029
14. Butterfield JM, Lodise TP, Beegle S (2014) Pharmacokinetics and pharmacodynamics of extendedinfusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother 69: 176-9. doi: 10.1093/jac/dkt300 PMID: 23869050
15. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56: 272-82. doi: 10.1093/cid/cis857 PMID: 23074314
16. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. (2005) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available: http://www.ohri.ca/ programs/clinical-epidemiology/oxford.htm. Accessed 10 May 2014.
17. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J (2010) First dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35: 156-63. doi: 10.1016/j.ijantimicag.2009.10. 008 PMID: 20018492
18. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J (2005) Pharmacokinetics of piperacillintazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25: 62-7. doi: 10. 1016/j.ijantimicag.2004.08.012
19. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, et al. (2006) Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 28: 122-7. doi: 10.1016/j.ijantimicag.2006.02.020 PMID: 16815689
20. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34. doi: 10.1136/bmj.315.7109.629 PMID: 9310563
21. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R (2002) Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 22: 471-83. doi: 10.1592/phco.22.7.471.33665 PMID: 11939682
22. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, et al. (2006) Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50: 3556-61. doi: 10.1128/AAC.00329-06 PMID: 16940077
23. DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP (2006) Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection. Am J Health Syst Pharm 63: 750-5. doi: 10.2146/ajhp050323 PMID: 16595817
24. Lodise TP, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44: 357-63. doi: 10.1086/510590 PMID: 17205441
25. Patel GW, Patel N, Lat A, Trombley K, Enbawe S, et al. (2009) Outcomes of extended infusion piperacillin/ tazobactam for documented gram-negative infections. Diagn Microbiol Infect Dis 64: 236-40. doi: 10.1016/j.diagmicrobio.2009.03.002 PMID: 19500529
26. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, et al. (2009) Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 33: 464-8. doi: 10.1016/j.ijantimicag.2008.10.025 PMID: 19150225
27. Li ZQ, Zhang YG, Wang CY, Qiu F (2010) Clinical efficacy of continuous infusion of piperacillin/tazobactam in severe pneumonia patients: a randomized controlled clinical trial. Modern Preventive Medicine 3: 2949-51.
28. Ye LQ, Cai T, Jin YH (2011) Clinical study of extending administration time of piperacillin/tazobactam in treatment of Gram-negative bacteria infection. Chin J Nosocomiol 21: 3476-79.
29. Yost RJ, Cappelletty DM (2011) The retrospective cohort of infusion piperacillin/tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 31: 767-75. doi: 10.1592/phco.31.8.767 PMID: 21923603
30. Gonçalves-Pereira J, Oliveira BS, Janeiro S, Estilita J, Monteiro C, et al. (2012) Continuous infusion of piperacillin/tazobactam in septic critically ill patients-a multicenter propensity matched analysis. PLoS One 7: e49845. doi: 10.1371/journal.pone.0049845 PMID: 23185458
31. Lee GC, Liou H, Yee R, Quan CF, Neldner K (2012) Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 34: 2297-300. doi: 10.1016/j. clinthera.2012.11.005 PMID: 23195962
32. Lü Y, Yan Z, Wang DH, Dong WL, Yang Y, et al. (2013) Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperaeillin/tazobactam:prolonged vs regular infusion. Chin Crit Care Med 25: 479-83.
33. Kasiakou SK, Lawrence KR, Choulis N, Falagas ME (2005) Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamics parameters. Drugs 65: 2499-511. doi: 10.2165/00003495-200565170-00006 PMID: 16296874
34. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, et al. (2005) Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56: 388-95. doi: 10.1093/jac/dki243 PMID: 16002420
35. Bandolier, Evidence And Diagnostics. Available: http://www.medicine.ox.ac.uk/bandolier/booth/ diagnos/Diagessy.html Accessed 10 July 2014.
36. Nelson EA (1999) Critical appraisal. 5. Randomised controlled trials: questions for valid evidence. NT Learn Curve 3: 6-8.
37. Austin PC, Alter DA, Tu JV (2003) The use of fixed- and random-effects models for classifying hospitals as mortality outliers: a Monte Carlo assessment. Med Decis Making 23: 526-39. doi: 10.1177/ 0272989X03258443 PMID: 14672113
38. Chen TA (2012) Fixed or random testlet effects: a comparison of two multilevel testlet models. J Appl Meas 13: 231-47. PMID: 23234827
39. Villar J, Mackey ME, Carroli G, Donner A (2001) Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models. Stat Med 20: 3635-47. doi: 10.1002/sim.1096 PMID: 11746343
40. Yoon YG, Koob MD (2005) Transformation of isolated mammalian mitochondria by bacterial conjugation. Nucleic Acids Res 33: e139. doi: 10.1093/nar/gni140 PMID: 16157861
41. Zhang J, Luo YP, Zhang XJ, Yao YH (2003) Resistant Mechanisms of Staphylococcus aureus: Analysis of Clinical Isolates to 20 Antimicrobial Agents. Chin J Nosocomiol 13: 1107-9.
42. Li XZ, Ling BD (2007) Progress in studying mechanisms of antimicrobial resistance in bacteria in 2006. Chin J of Antibiotics 32: 193-200.
43. Persson M, Løye AF, Mow T, Hornberg JJ (2013) A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 68: 302-13. doi: 10. 1016/j.vascn.2013.08.001 PMID: 23933113
44. Heinrich LS, Tokumaru S, Clark NM, Garofalo J, Paek JL, et al. (2011) Development and implementation of a piperacillin-tazobactam extended infusion guideline. J Pharm Pract 24: 571-6. doi: 10.1177/ 0897190011406984 PMID: 21676847
45. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J (2007) Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30: 11-8. doi: 10.1016/j. ijantimicag.2007.02.002 PMID: 17442541